Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB1 | P08588 | 9/20 | 0.41 |
| ▸ | ADRB3 | P13945 | 4/20 | 0.41 |
| ▸ | ADRB2 | P07550 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | NPY1R | P25929 | 1/20 | 0.40 |
| ▸ | NPY2R | P49146 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | ABCB1 | P08183 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5630866 | 0.97 | LMNA (0.38) | ADRB1ADRB3ADRB2LMNANPY1R | |
| SCHEMBL5630692 | 0.92 | LMNA (0.44) | ADRB1ADRB3ADRB2LMNANPY1R | |
| SCHEMBL5633531 | 0.92 | LMNA (0.38) | ADRB1ADRB3ADRB2LMNANPY1R | |
| SCHEMBL5630733 | 0.91 | LMNA (0.47) | ADRB1ADRB3ADRB2LMNANPY1R | |
| Hydrochloric Acid SCHEMBL5630410 | 0.91 | LMNA (0.37) | ADRB1ADRB3ADRB2LMNANPY1R | |
| SCHEMBL5633247 | 0.91 | LMNA (0.42) | ADRB3LMNANPY1RNPY2RMAPT | |
| SCHEMBL5632725 | 0.90 | LMNA (0.43) | ADRB1ADRB3ADRB2LMNANPY1R | |
| SCHEMBL5630860 | 0.89 | LMNA (0.38) | ADRB1ADRB3ADRB2LMNANPY1R | |
| Hydrochloric Acid SCHEMBL5631075 | 0.88 | LMNA (0.37) | ADRB1ADRB3ADRB2LMNANPY1R | |
| SCHEMBL8351693 | 0.85 | MAPT (0.43) | ADRB1ADRB3ADRB2LMNANPY1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1565472-A2 | COMPOUNDS WITH MIXED PDE-INHIBITORY AND BETA-ADRENERGIC ANTAGONIST OR PARTIAL AGONIST ACTIVITY FOR TREATMENT OF HEART FAILURE | Artesian Therapeutics, Inc. (US) | 2005-08-24 | — | — | EP | claimed |
| WO-2004050657-A2 | COMPOUNDS WITH MIXED PDE-INHIBITORY AND β-ADRENERGIC ANTAGONIST OR PARTIAL AGONIST ACTIVITY FOR TREATMENT OF HEART FAILURE | ARTESIAN THERAPEUTICS, INC. (US) | 2004-06-17 | — | — | WO | claimed |
| US-20070060748-A1 | Compounds with mixed pde-inhibitory and beta-adrenergic antagonist or partial agonist activity for treatment of heart failure | ARTESIAN THERAPEUTICS, INC. | 2007-03-15 | — | — | US | disclosed |
| EP-1565472-A2 | COMPOUNDS WITH MIXED PDE-INHIBITORY AND BETA-ADRENERGIC ANTAGONIST OR PARTIAL AGONIST ACTIVITY FOR TREATMENT OF HEART FAILURE | Artesian Therapeutics, Inc. (US) | 2005-08-24 | — | — | EP | disclosed |
| WO-2004050657-A2 | COMPOUNDS WITH MIXED PDE-INHIBITORY AND β-ADRENERGIC ANTAGONIST OR PARTIAL AGONIST ACTIVITY FOR TREATMENT OF HEART FAILURE | ARTESIAN THERAPEUTICS, INC. (US) | 2004-06-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070060748-A1 | Compounds with mixed pde-inhibitory and beta-adrenergic antagonist or partial agonist activity for treatment of heart failure | ADRB3, PDE3A, PDE3B | ADRB1 5/4885ADRB3 1/4885ADRB2 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.